CARLSBAD, Calif., Sept. 9,
2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc.
(Nasdaq: IONS) today announced a proposed underwritten public
offering of $500.0 million of its
common stock. Ionis intends to grant the underwriters a 30-day
option to purchase up to an additional $75.0
million of shares of its common stock offered in the public
offering on the same terms and conditions. Ionis intends to use the
net proceeds from the offering to fund its independent commercial
launches, late-stage clinical programs, earlier pipeline programs,
and research and development activities, as well as for working
capital and general corporate purposes. The offering is subject to
market and other conditions, and there can be no assurance as to
whether or when the offering may be completed, or as to the actual
size or terms of the offering.
Morgan Stanley and Goldman Sachs & Co. LLC are acting as
joint book-running managers for the offering.
A shelf registration statement relating to the offered
securities was filed with the Securities and Exchange Commission
("SEC") on November 24, 2023, and was
automatically effective upon filing. The offering is being made
only by means of a written prospectus and a prospectus supplement
that form a part of the registration statement. A preliminary
prospectus supplement and accompanying prospectus relating to the
offering will be filed with the SEC on September 9, 2024, and will be available for free
on the SEC's website, located at www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus
relating to this offering may be obtained from: Morgan Stanley
& Co. LLC, Attention: Prospectus Department, 180 Varick Street,
2nd Floor, New York, New York
10014, or by email at prospectus@morganstanley.com; and Goldman
Sachs & Co. LLC, Attention: Prospectus Department, 200 West
Street, New York, New York 10282,
by telephone at (866) 471-2526, or by email at
prospectus-ny@ny.email.gs.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Ionis Pharmaceuticals, Inc.
For three decades, Ionis has invented medicines that bring
better futures to people with serious diseases. Ionis currently has
five marketed medicines and a leading pipeline in neurology,
cardiology, and other areas of high patient need. As the pioneer in
RNA-targeted medicines, Ionis continues to drive innovation in RNA
therapies in addition to advancing new approaches in gene editing.
A deep understanding of disease biology and industry-leading
technology propels our work, coupled with a passion and urgency to
deliver life-changing advances for patients.
Forward-looking Statements
This press release includes forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such forward-looking statements include statements
regarding, among other things, Ionis' expectations regarding the
completion, timing and size of the proposed offering, Ionis'
expectations with respect to granting the underwriters a 30-day
option to purchase additional shares and Ionis' anticipated use of
the net proceeds from the proposed offering. Any statement
describing Ionis' goals, expectations, financial or other
projections, intentions, or beliefs is a forward-looking statement
and should be considered an at-risk statement. Words such as
"expect," "intends," "will," and similar expressions are intended
to identify forward-looking statements. Such statements are subject
to certain risks and uncertainties, including, but not limited to,
those related to Ionis' business and macroeconomic and geopolitical
events. These and other risks are described in additional detail in
the filings that Ionis makes with the SEC from time to time,
including Ionis' annual report on Form 10-K for the year ended
December 31, 2023, its subsequently
filed quarterly reports on Form 10-Q and the preliminary prospectus
supplement related to the proposed offering to be filed with the
SEC. Ionis' forward-looking statements involve assumptions that, if
they never materialize or prove correct, could cause its results to
differ materially from those expressed or implied by such
forward-looking statements. Although Ionis' forward-looking
statements reflect the good faith judgment of its management, these
statements are based only on facts and factors currently known by
Ionis. Except as required by law, Ionis undertakes no obligation to
update any forward-looking statements for any reason. As a result,
you are cautioned not to rely on these forward-looking
statements.
Ionis Pharmaceuticals Investor Contact:
D.
Wade Walke, Ph.D. – IR@ionis.com –
760-603-2331
Ionis Pharmaceuticals Media Contact:
Hayley Soffer – media@ionis.com –
760-603-4679
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ionis-announces-proposed-public-offering-of-common-stock-302242588.html
SOURCE Ionis Pharmaceuticals, Inc.